Author

S. H. Kaufmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Dobrovic· 2 shared C. L. Scott· 2 shared E. M. Swisher· 2 shared K. Nesic· 2 shared L. Zhang· 2 shared M. J. Wakefield· 2 shared M. R. Radke· 2 shared O. Kondrashova· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Dobrovic

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Cell-autonomous targeting of arabinogalactan by host immune factors inhibits mycobacterial growth

L. Qin, J. Xu, J. Chen, S. Wang, R. Zheng, Z. Cui, Z. Liu, X. Wu, J. Wang, X. Huang, Z. Wang, M. Wang, R. Pan, S. H. Kaufmann, X. Meng, , H. Liu

The paper identifies galectin-9 and AG-specific antibodies that inhibit Mtb growth by targeting arabinogalactan, offering a new immunotherapeutic strategy for TB.

bioRxiv · Oct 5, 2023Immunology

A Novel Subtype of Myeloproliferative Neoplasms Driven by a MYC-Alarmin Axis

N. D. Vincelette, X. Yu, A. T. Kuykendall, J. Moon, S. Su, C.-H. Cheng, R. Sammut, T. N. Razabdouski, H. V. Nguyen, E. A. Eksioglu, O. Chan, N. Al Ali, P. C. Patel, D. H. Lee, S. Nakanishi, , S. Yun

This study identifies a MYC-S100A9 axis driving triple negative myelofibrosis and shows it is a therapeutic target.

bioRxiv · Sep 25, 2023Cancer Biology

Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

R. M. Hurley, C. D. McGehee, K. Nesic, C. Correia, T. M. Weiskittel, R. L. Kelly, A. Venkatachalam, X. Hou, N. M. Pathoulas, X. W. Meng, O. Kondrashova, M. R. Radke, P. A. Schneider, K. S. Flatten, K. L. Peterson, , S. H. Kaufmann

This study shows that PARPi treatment can reverse RAD51C promoter methylation and restore expression in a high-grade serous ovarian cancer model, while maintaining platinum sensitivity.

bioRxiv · Dec 25, 2020Cancer Biology

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

K. Nesic, O. Kondrashova, R. M. Hurley, C. McGehee, C. J. Vandenberg, G.-Y. Ho, E. Lieschke, G. Dall, N. Bound, K. Shield-Artin, M. R. Radke, A. Musafer, Z. Qing Chai, M. R. Eftekhariyan Ghamsari, M. I. Harrell, , C. L. Scott

This study shows that loss of RAD51C promoter methylation leads to PARP inhibitor resistance in high-grade serous ovarian carcinoma, independent of BRCA1 methylation status.

bioRxiv · Dec 10, 2020Cancer Biology

RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik

This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.

bioRxiv · Dec 23, 2019 · PreprintCancer Biology